As of June 2026, according to Novartis AG's latest financial report, the company's current EPS (TTM) is $7.02. In 2025, the company recorded an earnings per share (EPS) of $7.21, which represents an increase compared to its EPS of $5.92 in 2024. Novartis AG's earnings per share for the quarterly report ending on Mar 31, 2026 was $1.65.
The annual EPS in 2025 was $7.21, an increase of 21.8% from $5.92 in 2024. For the quarter ending Mar 31, 2026, the EPS was $1.65, showing a 9.8% decrease from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $7.02. In 2024, the annual EPS was $5.92, showing a decrease of 17.2% from 2023.
Over the last 12 months, Novartis AG has registered an EPS growth of -9.8% (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS growth rate of 31.2% per year over the past 3 years. Over the last 5 years, the company had an average EPS growth rate of 15.2%. A 10-year view shows that NVS has seen an average EPS growth of -0.3% per year.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| BMY Bristol Myers Squibb Co | 15.41 | 178.7% | 5.3% | N/A |
| PFE Pfizer Inc | 18.97 | -3.5% | -37.4% | -3.7% |
| NVS Novartis AG | 21.58 | 21.8% | 31.2% | 15.2% |
| TEVA Teva Pharmaceutical Industries Ltd | 23.31 | 184.8% | N/A | N/A |
| ABT Abbott Laboratories | 24.61 | -51.4% | -1.8% | 8.2% |
| AZN Astrazeneca plc | 26.63 | 45.4% | 46% | 22% |
| JNJ Johnson & Johnson | 26.87 | 90.6% | 17.7% | 14.8% |
| MRK Merck & Co Inc | 32.61 | 8% | 8.4% | 21.2% |
All data is based on quarterly TTM periods, unless otherwise specified.